# Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

> **NCT00383851** · PHASE2 · UNKNOWN · sponsor: **Attenuon** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** ATN-224
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00383851
- **Lead sponsor:** Attenuon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2008-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2007-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383851, "Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00383851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*